This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentEventsMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

AboutEfficacySafetyDosingPortfolioSupportGroAssistEventsMaterialsVideos
Brought to you by Pfizer—a company committed to the pediatric growth hormone (GH) community1

For decades, Pfizer has been dedicated to supporting and improving the lives of patients with growth hormone disorders.1 

See how GENRYZON enables once-weekly dosing

Somatrogon is a long-acting protein known as a recombinant human growth hormone (rhGH), obtained through recombinant DNA technology. It contains 3 copies of naturally occurring C-terminal peptides (CTPs) to extend half-life.2

  • The CTPs in somatrogon are naturally occurring peptides derived from the beta chain of human chorionic gonadotropin (hCG)2,3
    •  The CTP of hCG contributes to longer serum half-life and has no effect on the interaction of the molecule with its receptor2,3
  • Adding 1 copy of hCG-derived CTP to the N-terminus and 2 copies to the C-terminus of rhGH extends half-life for somatrogon2,4
    • ​​​​​​​ The estimated half-life of somatrogon (0.66 mg/kg/week) is 28.2 hours versus 3.5 hours for daily GH (0.24 mg/kg/week)2,4
Learn about the GENRYZON mechanism of action2,3 

Coming Soon...

 Consider GENRYZON for all your appropriate patients age 3 years and older with pediatric GH deficiency2

Learn more about  GENRYZON Efficacy and Dosing. 

References:Genotropin. European Medicines Agency. Accessed January 10, 2022. https://www.ema.europa.eu/en/medicines/human/referrals/genotropinAdapted from GENRYZONTM Local Product Document: LPDGEN092022.Calo D, Hart G, Hoffman M, et al. Enhancing the longevity and in vivo potency of therapeutic proteins: the power of CTP. Precis Med. 2015;2:e989. doi:10.14800/pm.989 Zelinska N, Iotova V, Skorodok J, et al. Long-acting C-terminal peptide–modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017;102(5):1578‐1587.Zadik Z, Zelinska N, Iotova V, et al. Results from an open-label extension of the phase 2 dose-finding study of once weekly somatrogon vs daily Genotropin in pediatric patients with growth hormone deficiency (GHD). Poster 6887 presented at: Annual Meeting of the Endocrine Society [virtual]; March 20-23, 2021.Maniatis AK, Carakushansky M, Galcheva S, et al. Perception of treatment burden with once weekly somatrogon vs once daily Genotropin in pediatric patients with growth hormone deficiency: results from a randomized phase 3 study. Poster 6895 presented at: Annual Meeting of the Endocrine Society [virtual]; March 20-23, 2021.



 

PP-SMT-IND-0027,  05 OCT 2023

 

 EFFICACY

Height outcome comparable to daily GH in children with GH deficiency...with the benefit of fewer injections.2
View efficacy data
 SAFETY

5 years of clinical safety data in children with GH deficiency.5

 View safety data DOSING & ADMINISTRATION

Convenient, once-weekly administration.2,6

 See instructions
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-SMT-IND-0027

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023